Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.
暂无分享，去创建一个
C. Rudin | G. Shapiro | D. Camidge | C. Dive | L. Gandhi | S. Enschede | H. Xiong | Y. Chiu | T. Busman | A. Krivoshik | R. Humerickhouse | C. Hann | Moacyr Ribeiro de Oliveira | P. Bonomi | D. Gandara | D. Khaira | E. McKeegan | E. Litvinovich | P. Hemken | C. Nolan | E. Mckeegan